Patients with benign uterine diseases undergoing transvaginal natural orifice transluminal endoscopic surgery (vNOTES) hysterectomy
Conditions
Interventions
PCB with lidocaine (total 10 mL)
PCB with normal saline (total 10 mL) as placebo
Sponsors
Kobe City Nishi-Kobe Medical Center
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Patients scheduled to undergo VANH who have received a written explanation of the study and provided informed consent prior to surgery.
Exclusion criteria
Exclusion criteria: Patients who did not provide informed consent Patients with a history of hypersensitivity to local anesthetics Patients with contraindications to general anesthesia (ASA-PS >= 3) Patients with moderate to severe renal dysfunction (eGFR <= 50 mL/min/1.73 m2) Patients with severe hepatic dysfunction (Child-Pugh class B or C) Patients with chronic opioid use prior to surgery Patients with psychiatric or cognitive conditions that may interfere with reliable VAS assessment Patients deemed unsuitable for participation by the principal investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative pain assessed using the visual analog scale (VAS) at 6 hours after surgery. | — |
Countries
Japan
Contacts
Public ContactAi Kogiku
Kobe City Nishi-Kobe Medical Center Obstetrics and gynecology
Outcome results
None listed